Scarica l'app Stockscreener
54.10
1.55%
-0.85
Vaxcyte Inc Borsa (PCVX) Ultime notizie
Is now the right time to enter Vaxcyte Inc.Market Activity Report & Safe Capital Growth Tips - mfd.ru
Vaxcyte (PCVX) Initiates Phase 3 Trial for VAX-31 Vaccine in Adu - GuruFocus
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines - The Manila Times
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial - GlobeNewswire
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - Sahm
Vaxcyte, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 - Quiver Quantitative
Vaxcyte to Report Fourth Quarter and Full Year 2025 - GlobeNewswire
IPO Launch: What is the target price for Vaxcyte Inc stockMarket Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Valuation Update: Is Vaxcyte Inc affected by consumer sentimentSwing Trade & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Vaxcyte, Inc. $PCVX Shares Bought by Federated Hermes Inc. - MarketBeat
Aug Wrap: Does Stepan Company have consistent dividend growth2025 AllTime Highs & Fast Gain Swing Alerts - baoquankhu1.vn
How Investors May Respond To Vaxcyte (PCVX) Raising $550 Million To Fund Pneumococcal Vaccine Pipeline - Sahm
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit - 富途牛牛
Commit To Buy Vaxcyte At $45, Earn 19.3% Annualized Using Options - Nasdaq
Technical Reactions to PCVX Trends in Macro Strategies - Stock Traders Daily
Vaxcyte closes $632.5 million public offering of common stock By Investing.com - Investing.com India
Vaxcyte Completes Public Equity Offering, Bolstering Capital Position - The Globe and Mail
Is It Time To Reassess Vaxcyte (PCVX) After Recent Share Price Recovery - Yahoo Finance
Assessing Vaxcyte (PCVX) Valuation After Recent Share Price Momentum - Yahoo Finance
Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus - Yahoo Finance
Vaxcyte (NASDAQ:PCVX) Stock Price Up 8.1%Time to Buy? - MarketBeat
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring A Potential 90.61% Upside For Investors - DirectorsTalk Interviews
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Investing News Network
Vaxcyte Closes Public Offering of Shares - marketscreener.com
Vaxcyte closes $632.5 million public offering of common stock - Investing.com
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Vaxcyte, Inc. Completes $632.5 Million Public Offering of Common Stock - Quiver Quantitative
Guggenheim Reiterates Buy Rating on Vaxcyte (PCVX) at $116 Targe - GuruFocus
Vaxcyte (NASDAQ:PCVX) Earns Buy Rating from Guggenheim - MarketBeat
Sentiment Recap: Whats the RSI of Vaxcyte Inc stock2025 Retail Activity & AI Driven Stock Reports - baoquankhu1.vn
Top Biotech Stocks To Follow TodayFebruary 1st - MarketBeat
Vaxcyte launches proposed $500M public offering of stock, warrants - MSN
Vaxcyte prices $550 million public offering of common stock By Investing.com - Investing.com Nigeria
Eikon aims high for NASDAQ listing: Public Equity Report - BioCentury
Latham & Watkins Advises on Vaxcyte’s US$550 Million Public Offering - Latham & Watkins LLP
Vaxcyte launches $500 million public offering of common stock By Investing.com - au.investing.com
Biotech Stocks To Follow TodayJanuary 30th - MarketBeat
PCVX Increases Common Stock Offering to $550 Million - GuruFocus
Vaxcyte (NASDAQ:PCVX) Shares Gap UpStill a Buy? - MarketBeat
Vaccine maker looks to raise half a billion dollars to attack an $8 billion market - The Business Journals
Vaxcyte edges higher after upsized $550 mln equity raise - TradingView
Vaxcyte Secures $550 Million to Advance Vaccine Pipeline and Manufacturing - AD HOC NEWS
Vaxcyte Prices $550 Million Common Stock Offering - marketscreener.com
Vaxcyte Announces Pricing of $550 Million Public Offering - Investing News Network
Vaxcyte prices $550 million public offering of common stock - Investing.com
Vaxcyte sells 11M new shares in $550M stock offering at $50 - stocktitan.net
PCVX Offering Managed by Top Financial Firms - GuruFocus
Vaxcyte (PCVX) Launches Share Offering Priced at $50 - GuruFocus
1.12%
0.87%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):